Drugs for Gastrointestinal Diseases Practice Questions

Q: Activation of which type of receptors present on myenteric neurons by metoclopramide is primarily responsible for the enhanced acetylcholine release and improving gastric motility?

Serotonergic 5-HT4. ### Explanation **Correct Option: C. Serotonergic 5-HT4** Metoclopramide is a substituted benzamide that acts as a **prokinetic agent**. Its primary mechanism for enhancing gastrointestinal motility is the **agonism of 5-HT4 receptors** located on the presynaptic terminals of excitatory myenteric neurons. Activation of these receptors triggers the release of **Acetylcholine (ACh)** at the neuromuscular junction, which stimulates the smooth muscle of the stomach and upper intestine, leading to increased gastric emptying and intestinal transit [1]. **Analysis of Incorrect Options:** * **A. Muscarinic M1:** While ACh eventually acts on M3 receptors on smooth muscles to cause contraction, metoclopramide does not directly activate M1 receptors to enhance motility. * **B. Serotonergic 5-HT3:** Metoclopramide is a 5-HT3 **antagonist**. This action occurs primarily in the Chemoreceptor Trigger Zone (CTZ) and contributes to its **antiemetic** properties, not its prokinetic effect. * **D. Dopaminergic D2:** Metoclopramide is a D2 receptor antagonist. While D2 blockade in the GI tract contributes slightly to the prokinetic effect (as dopamine inhibits ACh release), the **primary** and more potent driver of gastric motility is 5-HT4 agonism. D2 blockade in the CTZ is also responsible for its antiemetic effect. **High-Yield Clinical Pearls for NEET-PG:** * **Dual Action:** Metoclopramide is both a prokinetic (via 5-HT4 agonism) and an antiemetic (via D2 and 5-HT3 antagonism). * **Side Effects:** Due to central D2 blockade, it can cause **extrapyramidal symptoms** (dystonias, Parkinsonism) and **hyperprolactinemia** (galactorrhea, gynecomastia). * **Drug of Choice:** It is frequently used in diabetic gastroparesis and as an antiemetic in postoperative nausea. * **Contraindication:** Never use in cases of mechanical GI obstruction or pheochromocytoma (may cause hypertensive crisis).

Q: Which anticholinergic drug has a comparatively specific action on gastric secretion and is useful in peptic ulcer?

Pirenzepine. **Explanation:** The correct answer is **Pirenzepine**. **1. Why Pirenzepine is correct:** Pirenzepine is a selective **M1-receptor antagonist** [1]. In the stomach, M1 receptors are located on the intramural ganglia of the vagus nerve. By blocking these receptors, pirenzepine inhibits the release of acetylcholine, which in turn reduces gastric acid secretion from parietal cells [1]. Unlike non-selective anticholinergics, it has a higher affinity for gastric M1 receptors than for M2 (heart) or M3 (smooth muscle/glands) receptors, allowing it to reduce acid secretion at doses that do not significantly cause typical anticholinergic side effects like tachycardia or dry mouth [1]. **2. Why the other options are incorrect:** * **Atropine:** A prototype non-selective muscarinic antagonist [1]. It blocks M1, M2, and M3 receptors equally [3]. To inhibit gastric acid, it requires high doses that cause intolerable side effects (blurred vision, urinary retention, tachycardia) [1], [2]. * **Oxyphenonium bromide:** A potent non-selective synthetic anticholinergic. While used as an antispasmodic and adjunct in peptic ulcers, it lacks the M1-selectivity of pirenzepine. * **Dicyclomine:** Primarily acts as a direct smooth muscle relaxant and M3 antagonist [4]. It is used as an **antispasmodic** for Irritable Bowel Syndrome (IBS) and abdominal colic, rather than for suppressing gastric acid [4]. **NEET-PG High-Yield Pearls:** * **Telenzepine** is another M1-selective antagonist, even more potent than pirenzepine [1]. * While pirenzepine is pharmacologically significant, it is rarely used clinically today due to the superior efficacy of **Proton Pump Inhibitors (PPIs)** and H2 blockers. * **M1 Receptors:** Located in Autonomic ganglia and CNS [3]. * **M2 Receptors:** Located in the Heart (SA/AV node). * **M3 Receptors:** Located in Smooth muscles, Exocrine glands, and Vascular endothelium.

Q: Which of the following drugs is not used for H. pylori treatment?

Oxytetracycline. **Explanation:** The standard treatment for *Helicobacter pylori* involves a combination of antibiotics and acid-suppressing agents to ensure eradication and prevent peptic ulcer recurrence. **1. Why Oxytetracycline is the correct answer:** While **Tetracycline (HCl)** is a core component of the classic bismuth-based quadruple therapy, **Oxytetracycline** is not used. In the context of *H. pylori*, Tetracycline is preferred due to its specific pharmacokinetic profile and proven efficacy in eradication protocols. Oxytetracycline is generally less potent and lacks clinical evidence for treating this specific gastric infection. **2. Analysis of incorrect options:** * **Bismuth compounds (B):** Used in quadruple therapy (e.g., Bismuth subsalicylate/subcitrate). They exert direct toxic effects on the bacilli and prevent bacterial adhesion to the gastric mucosa. * **Clarithromycin (C):** A macrolide antibiotic that inhibits bacterial protein synthesis. It is the "backbone" of the standard Triple Therapy (Clarithromycin + Amoxicillin + PPI). * **Omeprazole (D):** A Proton Pump Inhibitor (PPI). PPIs are essential because they increase gastric pH, which enhances the stability and efficacy of the co-administered antibiotics. **Clinical Pearls for NEET-PG:** * **Standard Triple Therapy (14 days):** PPI + Clarithromycin + Amoxicillin (or Metronidazole if penicillin-allergic). * **Quadruple Therapy:** PPI + Bismuth + Metronidazole + **Tetracycline**. * **Pylera:** A 3-in-1 capsule containing Bismuth, Metronidazole, and Tetracycline. * **Drug of choice for H. pylori:** Clarithromycin-based triple therapy remains the first-line treatment unless local resistance is >15%.

Q: Which antiulcer agent detaches from and kills H. Pylori, thereby preventing relapses?

Colloidal Bismuth. **Explanation:** The correct answer is **Colloidal Bismuth Subcitrate (CBS)**. **Why Colloidal Bismuth is correct:** Colloidal Bismuth acts via multiple mechanisms to treat peptic ulcers. Unlike most antiulcer drugs that merely reduce acid or provide a physical barrier, Bismuth compounds possess direct **antimicrobial activity** against *H. pylori*. 1. **Detachment:** It prevents the adhesion of *H. pylori* to the gastric epithelium. 2. **Bactericidal Action:** It causes lysis of the bacterial wall and inhibits its enzymes (like urease and phospholipase). By eradicating the bacteria, it significantly reduces the rate of ulcer relapse compared to drugs that only suppress acid. **Why other options are incorrect:** * **Pirenzepine:** An M1-selective anticholinergic that reduces gastric acid secretion. It has no effect on *H. pylori* and is rarely used due to the superiority of PPIs. * **Misoprostol:** A PGE1 analogue that increases mucosal bicarbonate/mucus and decreases acid. It is primarily used for preventing NSAID-induced ulcers but lacks antimicrobial properties. * **Sucralfate:** A physical mucosal protectant that polymerizes at pH < 4 to form a "sticky paste" over the ulcer base. While it provides a barrier, it does not kill *H. pylori*. **High-Yield NEET-PG Pearls:** * **Bismuth Quadruple Therapy:** Consists of a PPI + Bismuth + Metronidazole + Tetracycline (used as first-line or for resistant *H. pylori*). * **Side Effects:** Bismuth can cause **black discoloration of stools and tongue** (may be confused with melena) and, rarely, encephalopathy with long-term use. * **Sucralfate Requirement:** It requires an acidic medium for activation; therefore, it should **not** be given simultaneously with antacids or PPIs.

Q: Which of the following drugs has the least affinity for CYP3A4?

Rabeprazole. **Explanation:** The correct answer is **Rabeprazole**. **1. Underlying Medical Concept:** Proton Pump Inhibitors (PPIs) are primarily metabolized in the liver by the cytochrome P450 system, specifically **CYP2C19** and **CYP3A4**. The degree of reliance on these enzymes determines the potential for drug-drug interactions (e.g., with Clopidogrel or Warfarin). **Rabeprazole** is unique because it is predominantly metabolized via a **non-enzymatic pathway** (reduction to rabeprazole thioether) with only minor involvement of the CYP system. Consequently, it has the least affinity for CYP3A4 and CYP2C19 among the PPIs, making its pharmacokinetics less affected by genetic polymorphisms or concurrent drug use. **2. Analysis of Incorrect Options:** * **Omeprazole (A):** This is the prototype PPI and has the **highest affinity** for CYP2C19 and significant affinity for CYP3A4. It is a potent inhibitor of these enzymes, leading to many drug interactions. * **Esomeprazole (C):** As the S-isomer of omeprazole, it is also heavily metabolized by CYP2C19 and CYP3A4, though it shows slightly improved bioavailability. * **Lansoprazole (B):** This drug is extensively metabolized by both CYP2C19 and CYP3A4. While it has a shorter half-life, its dependence on the CYP system is much higher than that of Rabeprazole. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice for Drug Interactions:** Rabeprazole and **Pantoprazole** are the preferred PPIs for patients on multiple medications (polypharmacy) due to their lower potential for CYP-mediated interactions. * **Clopidogrel Interaction:** Omeprazole inhibits CYP2C19, which prevents the conversion of Clopidogrel (a prodrug) into its active form, increasing the risk of cardiovascular events. * **Genetic Polymorphism:** The efficacy of Omeprazole varies significantly between "Poor Metabolizers" and "Extensive Metabolizers" of CYP2C19; Rabeprazole avoids this variability.

Q: Which of the following is NOT a clinical use of Metoclopramide?

Motion sickness. **Explanation:** Metoclopramide is a **D2 receptor antagonist** that also possesses 5-HT4 agonistic and weak 5-HT3 antagonistic properties. It acts both centrally in the Chemoreceptor Trigger Zone (CTZ) and peripherally as a prokinetic agent. **1. Why Option A is correct (Motion Sickness):** Motion sickness is primarily mediated by the **vestibular system**, where H1 (histamine) and M1 (muscarinic) receptors predominate. Metoclopramide has no significant antihistaminic or anticholinergic activity. Therefore, it is **ineffective** in treating motion sickness. Drugs of choice for motion sickness include Hyoscine (anticholinergic) or Promethazine (antihistaminic). **2. Why other options are incorrect:** * **Option B (Chemotherapy-induced vomiting):** Metoclopramide is used in high doses to treat chemotherapy-induced nausea and vomiting (CINV) because, at high concentrations, it blocks 5-HT3 receptors in the CTZ. However, it has largely been superseded by Ondansetron. * **Option C (As an antiemetic):** It is a potent antiemetic used for post-operative vomiting and vomiting associated with systemic diseases (uremia, radiation sickness) due to its D2 blockade in the CTZ. **Clinical Pearls for NEET-PG:** * **Prokinetic Action:** It increases lower esophageal sphincter (LES) tone and promotes gastric emptying, making it useful in **Diabetic Gastroparesis** and GERD. * **Side Effects:** Due to central D2 blockade, it can cause **Extrapyramidal Symptoms (EPS)** like acute dystonia and Parkinsonism. It also causes **Hyperprolactinemia** (leading to galactorrhea/gynecomastia). * **Contraindication:** It should never be used in cases of **mechanical intestinal obstruction** or pheochromocytoma.

Q: What is the primary function of infliximab in the management of Crohn's disease?

Inhibition of Tumor Necrosis Factor-alpha (TNF-α). **Explanation:** **1. Why Option A is Correct:** Infliximab is a chimeric monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of **Tumor Necrosis Factor-alpha (TNF-α)**. In Crohn’s disease, TNF-α is a key pro-inflammatory cytokine that drives the chronic transmural inflammation of the bowel. By neutralizing TNF-α, infliximab prevents it from binding to its receptors, thereby reducing mucosal inflammation and promoting the healing of fistulas. **2. Why Other Options are Incorrect:** * **Option B (IL-2 Inhibition):** Drugs like Basiliximab or Daclizumab inhibit IL-2 receptors. These are primarily used as immunosuppressants in organ transplantation, not as first-line biologics for Crohn's. * **Option C (EGFR Inhibition):** Drugs like Cetuximab and Erlotinib target EGFR. These are used in the treatment of various malignancies (e.g., colorectal cancer, NSCLC) but have no role in managing inflammatory bowel disease (IBD). * **Option D (VEGF Inhibition):** Bevacizumab is a VEGF inhibitor used to inhibit angiogenesis in cancers and age-related macular degeneration. It is not used for IBD. **3. NEET-PG High-Yield Clinical Pearls:** * **Route of Administration:** Infliximab is given via **Intravenous (IV)** infusion, whereas Adalimumab (another TNF-α inhibitor) is given subcutaneously. * **Pre-treatment Screening:** Before starting Infliximab, patients **must** be screened for **Latent Tuberculosis (TB)** using a TST or IGRA, as TNF-α inhibitors can cause reactivation of TB. * **Other Indications:** Infliximab is also used in Ulcerative Colitis, Rheumatoid Arthritis, and Psoriasis. * **Adverse Effect:** Formation of "Antidrug Antibodies" (ADAs) can lead to loss of clinical response over time.

Q: Anthranol acts as a purgative due to which of the following mechanisms?

Irritant action. ### Explanation **Correct Option: A. Irritant action** Anthranol (and its derivatives like Anthraquinones) belongs to the class of **Stimulant or Irritant Purgatives**. These drugs act primarily in the colon. Once ingested, they are hydrolyzed by colonic bacteria into active metabolites (like emodin) that directly irritate the intestinal mucosa. This irritation leads to two primary effects: 1. **Increased Peristalsis:** Direct stimulation of the myenteric plexus increases propulsive activity. 2. **Altered Electrolyte Transport:** They inhibit Na⁺/K⁺-ATPase and increase prostaglandin synthesis, leading to the accumulation of water and electrolytes in the lumen. **Analysis of Incorrect Options:** * **B. Bulk formation:** This is the mechanism for agents like **Psyllium (Isabgol)** and **Methylcellulose**. They absorb water, swell, and increase the volume of intestinal contents, which mechanically stimulates peristalsis. * **C. Osmotic action:** This is seen with **Magnesium salts (Milk of Magnesia)** and **Lactulose**. These agents are non-absorbable and draw water into the lumen via osmosis, softening the stool and distending the bowel. * **D. Emollient effect:** This refers to **Stool Softeners** like **Docusate** or **Liquid Paraffin**, which act as surfactants to allow water and lipids to penetrate the fecal mass. **High-Yield Clinical Pearls for NEET-PG:** * **Anthraquinone examples:** Senna, Cascara, and Aloe. * **Melanosis Coli:** Chronic use of anthraquinone purgatives can lead to a characteristic brownish-black pigmentation of the colonic mucosa. * **Latency:** These drugs typically take 6–12 hours to act because they must reach the colon and be activated by bacterial flora. * **Contraindication:** Stimulant purgatives should be avoided in undiagnosed abdominal pain or intestinal obstruction.

Q: Which drug is absolutely contraindicated in a pregnant lady suffering from peptic ulcer?

Misoprostol. ### Explanation **Correct Option: C. Misoprostol** **Why Misoprostol is the Correct Answer:** Misoprostol is a synthetic **Prostaglandin E1 (PGE1) analogue**. While it is effective in treating NSAID-induced peptic ulcers by increasing gastric mucus production and decreasing acid secretion, it is **absolutely contraindicated (FDA Pregnancy Category X)** in pregnant women. Misoprostol possesses potent **uterotonic properties**, causing strong uterine contractions and cervical ripening. These effects can lead to partial or complete **abortion**, premature labor, or fetal death. In clinical practice, it is actually used legally for medical termination of pregnancy (MTP) and induction of labor, making its use in a continuing pregnancy dangerous. **Why Other Options are Incorrect:** * **A. Omeprazole:** A Proton Pump Inhibitor (PPI). It is generally considered safe in pregnancy (Category C/B). While not the first-line choice, it is used when H2 blockers fail. * **B & D. Ranitidine and Famotidine:** These are H2-receptor antagonists. They are considered **safe** and are often the first-line pharmacological treatment for GERD or peptic ulcers in pregnancy if lifestyle modifications fail. They do not possess teratogenic or oxytocic properties. **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC)** for GERD/Peptic Ulcer in pregnancy: **Sucralfate** (due to negligible systemic absorption) or **H2 blockers** (Ranitidine/Famotidine). * **Misoprostol Side Effects:** The most common side effect is **diarrhea** and abdominal cramps. * **Clinical Use:** Misoprostol is the DOC for **prevention of NSAID-induced ulcers** in non-pregnant patients and is used in the management of **Postpartum Hemorrhage (PPH)**. * **Teratogenicity:** If a pregnancy continues after misoprostol exposure, there is a risk of **Möbius syndrome** (congenital facial paralysis).

Question 1

Activation of which type of receptors present on myenteric neurons by metoclopramide is primarily responsible for the enhanced acetylcholine release and improving gastric motility?

Accepted Answer

Serotonergic 5-HT4

Answer

Muscarinic M1

Answer

Serotonergic 5-HT3

Answer

Dopaminergic D2

Question 2

Which anticholinergic drug has a comparatively specific action on gastric secretion and is useful in peptic ulcer?

Accepted Answer

Pirenzepine

Answer

Atropine

Answer

Oxyphenonium bromide

Answer

Dicyclomine

Question 3

Which of the following drugs is not used for H. pylori treatment?

Accepted Answer

Oxytetracycline

Answer

Bismuth compounds

Answer

Clarithromycin

Answer

Omeprazole

Question 4

Which antiulcer agent detaches from and kills H. Pylori, thereby preventing relapses?

Accepted Answer

Colloidal Bismuth

Answer

Pirenzipine

Answer

Misoprostol

Answer

Sucralfate

Question 5

Which of the following drugs has the least affinity for CYP3A4?

Accepted Answer

Rabeprazole

Answer

Omeprazole

Answer

Lansoprazole

Answer

Esomeprazole

Question 6

Which of the following is NOT a clinical use of Metoclopramide?

Accepted Answer

Motion sickness

Answer

Chemotherapy-induced vomiting

Answer

As an antiemetic

Answer

All of the above are uses of Metoclopramide

Question 7

What is the primary function of infliximab in the management of Crohn's disease?

Accepted Answer

Inhibition of Tumor Necrosis Factor-alpha (TNF-α)

Answer

Inhibition of Interleukin-2 (IL-2)

Answer

Epidermal Growth Factor Receptor (EGFR) inhibition

Answer

Inhibition of Vascular Endothelial Growth Factor (VEGF)

Question 8

The therapeutic effect of sulfasalazine in ulcerative colitis is exerted by which mechanism?

Accepted Answer

Breakdown of the drug in the colon to release 5-aminosalicylic acid, which suppresses inflammation locally.

Answer

Inhibitory action of the unabsorbed drug on the abnormal colonic flora.

Answer

Release of sulfapyridine having antibacterial properties.

Answer

Systemic immunomodulatory action of the drug.

Question 9

Anthranol acts as a purgative due to which of the following mechanisms?

Accepted Answer

Irritant action

Answer

Bulk formation in the intestinal lumen

Answer

Osmotic action

Answer

Emollient effect

Question 10

Which drug is absolutely contraindicated in a pregnant lady suffering from peptic ulcer?

Accepted Answer

Misoprostol

Answer

Omeprazole

Answer

Ranitidine

Answer

Famotidine

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?